CbsBioscience

Innovative science

Technology

Global network

CbsBioscience retains enormous clinical and experimental data through establishment of strong global clinical research network by conducting collaborative research in 7 types of cancers

Domestic: KCSG 102 hospitals, K-MASTER 53 hospitals, and KCBC 13 hospitals
International: 2 countries (Italy, Japan)

KCBC
Korea Cancer Biomarker Consortium

Participated Hospitals : 13

New Health Technology : Liver Cancer Prognostic test
OncoHepaTest®
Nexavar® CDx clinical trial
Biomarker to predict TACE response

KCSG
Korean Cancer Study Group

Participated Hospitals : 102

Head and Neck Cancer
Small Cell Lung Cancer
Sarcomatoid Carcinoma
Salivary Gland Tumor
Will Expand to other Cancer Types

K-MASTER
Cancer Precision Medicine Diagnosis and Treatment Enterprise

Participated Hospitals : 53

Triple-Negative Breast Cancer patients’ clinico-genomic data analysis
Expand to all cancer types, Big data based tailored treatment analysis

Italy I.R.C.C.S

MOU signed for biomarker development
nCounter based Nexavar® biomarker validation
Liver Cancer prognostic test OncoHepa validation on Italian cohort

Japan WHMU

MOU signed for biomarker development
Completion of liver cancer prognostic test OncoHepa validation on Japanese cohort
nCounter based Nexavar® biomarker validation

Other Partners

Nanostring
BMS